viewZelira Therapeutics Ltd

Zelira Therapeutics halted ahead of a licensing agreement in the United States

The global therapeutic medicinal cannabis company owns a portfolio of proprietary products positioned to enter global markets from 2020.

Zelira Therapeutics Ltd - Zelira Therapeutics in trading halt ahead of a licence agreement in the United States
Zelira has undertaken pilot clinical studies in Chile to assess the efficacy of medicinal cannabis formulations in children diagnosed with autism

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) is in a trading halt ahead of an announcement in relation to a licensing agreement in the United States of America

The trading halt will remain in place until the beginning of regular ASX trade on Wednesday, July 22, or when an announcement is released to the market, whichever occurs earliest.

Shares last traded at 5.3 cents and are up from 2.2 cents at the close on March 23.

Phase-1 dose-escalation trial

Zelira’s final clinical report for a Phase 1 dose-escalation trial in chronic pain patients on long-term high-dose opioid treatment has demonstrated that the primary and secondary endpoints for safety and efficacy were met.

The study at St Vincent’s Hospital in Melbourne in conjunction with Emerald Clinics Ltd (ASX:EMD) in Perth, was conducted to assess the safety of Zelira's cannabis formulation (ZTL-103) in seven chronic pain patients already using high doses of opioids.

These patients all completed the study and were treated with a single sublingual dose of ZTL-103 containing 5 milligrams of total cannabinoids (2.5 milligrams THC and 2.5 milligrams CBD) on the first day.

After a seven-day washout, they received a 5-milligram dose at the same time as having a high-fat meal and continued to take two daily doses of 5 milligrams for seven days, before escalating to 20 milligrams per day for seven days, then up to 30 milligrams for a further seven days before taking a single dose of 25 milligrams.

The trial showed ZTL-103 is safe, with no serious adverse events reported, non-serious adverse events were mild and the maximal dose was generally well tolerated.

Quick facts: Zelira Therapeutics Ltd

Price: 0.079 AUD

Market: ASX
Market Cap: $93.64 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...


Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

2 weeks, 1 day ago

2 min read